Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

News SummaryMost relevantAll newsSector newsTweets

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
04/28/2012 | 12:29am CEST

--Judge rules U.S. patent for Vytorin and Zetia is valid and enforceable

--Mylan had challenged patent in bid to sell generic Vytorin and Zetia

--Merck patent due to expire in April 2017

(Adds statement from Merck, additional details.)

   By Peter Loftus 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said the patent for was valid and enforceable. The patent covers ezetimibe, an active ingredient in both Zetia and Vytorin.

Merck, based in Whitehouse Station, N.J., said the U.S. patent for Vytorin and Zetia is due to expire in April 2017.

"The court appropriately ruled that the patent for Zetia and Vytorin in the U.S. is valid and enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent expired, arguing that the patent was invalid and unenforceable.

Merck filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's plan to sell generic Vytorin, and in 2010 sued to block Mylan from selling generic Zetia. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

Merck said the court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent.

A Mylan spokeswoman couldn't immediately be reached for comment.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; [email protected]

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
09/23 AGILENT TECHNOLOGIES : Receives Expanded FDA Approval for Use of Dako PD-L1 IHC ..
09/22 MERCK AND : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously ..
09/22 MERCK AND : Drug Makers Stocks on Investors' Radar -- Alliqua BioMedical, Immune..
09/21 MERCK AND : MSD`s Keytruda wins new bladder cancer indication in Europe
09/19 MERCK AND : Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Me..
09/14 MERCK AND : Rigontec Acquired by MSD
09/14 MERCK AND COMPANY : ex-dividend day
09/12 NOW AVAILABLE IN CANADA : ISENTRESS® HD (raltegravir), a New Once-Daily Option, ..
09/12 MERCK AND : KEYTRUDA Plus Pemetrexed and Carboplatin Demonstrated Continued Bene..
09/12 MERCK AND : KEYTRUDA Continues to Show Overall Survival Benefit over Chemotherap..
More news
News from SeekingAlpha
09/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 23, 2017
09/22 FDA OKs Merck's Keytruda for gastric cancer
09/22 REDHILL BIOPHARMA : Highly De-Risked And Undervalued With A Deep Pipeline
09/21 FDA's Woodcock says clinical trials system "broken"
09/21 Mirati Brings Hope With Its Stellar Performance
Financials ($)
Sales 2017 40 323 M
EBIT 2017 13 721 M
Net income 2017 5 623 M
Debt 2017 7 139 M
Yield 2017 2,89%
P/E ratio 2017 32,52
P/E ratio 2018 19,43
EV / Sales 2017 4,58x
EV / Sales 2018 4,48x
Capitalization 178 B
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,1 $
Spread / Average Target 7,6%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY11.43%177 633
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
SANOFI9.39%126 921